State Street SPDR S&P Biotech ETF
761 hedge funds and large institutions have $9.17B invested in State Street SPDR S&P Biotech ETF in 2024 Q2 according to their latest regulatory filings, with 88 funds opening new positions, 254 increasing their positions, 255 reducing their positions, and 98 closing their positions.
0% less repeat investments, than reductions
Existing positions increased: 254 | Existing positions reduced: 255
2.15% less ownership
Funds ownership: 130.81% → 128.67% (-2.1%)
2% less funds holding
Funds holding: 780 → 761 (-19)
6% less capital invested
Capital invested by funds: $9.75B → $9.17B (-$577M)
10% less first-time investments, than exits
New positions opened: 88 | Existing positions closed: 98
22% less funds holding in top 10
Funds holding in top 10: 23 → 18 (-5)
46% less call options, than puts
Call options by funds: $1.59B | Put options by funds: $2.95B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$402M |
| 2 |
Goldman Sachs
New York
|
+$186M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$146M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$120M |
| 5 |
Two Sigma Advisers
New York
|
+$32.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$167M |
| 2 |
Citigroup
New York
|
-$140M |
| 3 |
CHP
Castle Hook Partners
New York
|
-$131M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$113M |
| 5 |
Morgan Stanley
New York
|
-$79.9M |
XBI Hedge Fund Activity: Q2 2024 in Review
761 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q2 2024, worth a combined $9.17B — down 5.9% from $9.75B a quarter earlier.
Sellers outnumbered buyers: 98 funds closed out of XBI and 88 opened new positions — a net loss of 10 holders — while 255 trimmed existing stakes and 254 added.
The largest buyer was JP Morgan Chase, adding an estimated $402M. The largest seller was Citadel Advisors, cutting an estimated $167M.
- 761 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q2 2024, down from 780 in Q1 2024.
- Funds reported $9.17B of State Street SPDR S&P Biotech ETF stock for Q2 2024, down 5.9% quarter-over-quarter.
- 88 funds opened new State Street SPDR S&P Biotech ETF positions in Q2 2024 and 98 closed out, a net change of -10 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q2 2024 was JP Morgan Chase, an estimated $402M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q2 2024 was Citadel Advisors, an estimated $167M sold.
Based on aggregated 13F filings for Q2 2024.